Host: Sara M. Tolaney MD, MPH This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs ac

Host: Sara M. Tolaney MD, MPH This program provides education to help clinicians confidently diagnose and make informed clinical decisions with their patients, ultimately enhancing clinical outcomes in the evolving treatment landscape of ADCs ac

Host: John L. Marshall, MD Gastric and gastroesophageal junction cancers are the third most common cause of cancer deaths globally. In this Chairmans Perspective, Dr. John Marshall breaks down the latest data from the 2023 World Congress on GI

Guest: Petros Grivas, MD, PhD Guest: Thomas Powles, MD, PhD Survival for patients with metastatic urothelial cancer has increased with the approval of immune therapy, antibody-drug conjugates, and targeted agents. In the maintenance setting,

Guest: Tiffany Traina, MD, FASCO Guest: Gregory Vidal, MD, PhD Guest: Stephanie Walker, RN Despite recent advances, triple-negative breast cancer (TNBC) remains difficult to treat due to a poor prognosis and a small number of effective t

Host: Tara C. Mitchell, MD This program is designed to improve clinicians’ knowledge of the latest clinical trial data surrounding the use of immunotherapy for the adjuvant treatment of patients with melanoma. The program addresses clinical chal

Host: Nikhil I. Khushalani, MD This program is designed to improve clinicians’ knowledge of the latest clinical trial data surrounding the use of immunotherapy for the adjuvant treatment of patients with melanoma. The program addresses clinical

Host: Erica L. Mayer, MD, MPH This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER

Host: Sarah Sammons, MD This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstrated benefit not only in HER2+ dis

Host: Erica L. Mayer, MD, MPH Host: Sarah Sammons, MD This program explores new evidence that challenges the binary paradigm of HER2+ versus HER2- disease. Evidence is now available that specific antibody-drug conjugates (ADCs) have demonstr